1. DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients. (30th January 2023) Authors: Hageman, I; Joustra, V; Zafeiropoulou, K; Davids, M; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P09.05 Exploring the therapeutic vulnerabilities of cathepsin S hyperactive tumors. (21st September 2022) Authors: Hildebrand, J; Rengasayee, P; Antoniolli, M; Hackett, L; Adolph, L; Häbe, S; Heide, M; Wilhelm, S; Ludwig, C; Strobl, C; Passerini, V; Bergwelt-Baildon, M; Koch, R; Davids, M; Weigert, O Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn's Disease. (21st January 2022) Authors: Radford-Smith, D; Yates, A; Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; D'Haens, G; de Jong, W; Anthony, D; Satsangi, J; Probert, F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P707 Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease. (21st January 2022) Authors: Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗